JP2022548688A5 - - Google Patents

Info

Publication number
JP2022548688A5
JP2022548688A5 JP2022517369A JP2022517369A JP2022548688A5 JP 2022548688 A5 JP2022548688 A5 JP 2022548688A5 JP 2022517369 A JP2022517369 A JP 2022517369A JP 2022517369 A JP2022517369 A JP 2022517369A JP 2022548688 A5 JP2022548688 A5 JP 2022548688A5
Authority
JP
Japan
Prior art keywords
dosage form
form according
disease
hydroxypropyl methylcellulose
bms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022517369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548688A (ja
JP7719770B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/051341 external-priority patent/WO2021055651A1/en
Publication of JP2022548688A publication Critical patent/JP2022548688A/ja
Publication of JP2022548688A5 publication Critical patent/JP2022548688A5/ja
Priority to JP2025124835A priority Critical patent/JP2025163082A/ja
Application granted granted Critical
Publication of JP7719770B2 publication Critical patent/JP7719770B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022517369A 2019-09-18 2020-09-18 Tyk2阻害薬の徐放性剤形 Active JP7719770B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025124835A JP2025163082A (ja) 2019-09-18 2025-07-25 Tyk2阻害薬の徐放性剤形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902218P 2019-09-18 2019-09-18
US62/902,218 2019-09-18
PCT/US2020/051341 WO2021055651A1 (en) 2019-09-18 2020-09-18 Extended release dosage forms for tyk2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025124835A Division JP2025163082A (ja) 2019-09-18 2025-07-25 Tyk2阻害薬の徐放性剤形

Publications (3)

Publication Number Publication Date
JP2022548688A JP2022548688A (ja) 2022-11-21
JP2022548688A5 true JP2022548688A5 (cg-RX-API-DMAC7.html) 2023-09-27
JP7719770B2 JP7719770B2 (ja) 2025-08-06

Family

ID=72670853

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022517369A Active JP7719770B2 (ja) 2019-09-18 2020-09-18 Tyk2阻害薬の徐放性剤形
JP2022517368A Active JP7812785B2 (ja) 2019-09-18 2020-09-18 Tyk2阻害薬の剤形
JP2025124835A Pending JP2025163082A (ja) 2019-09-18 2025-07-25 Tyk2阻害薬の徐放性剤形
JP2026012729A Pending JP2026090315A (ja) 2019-09-18 2026-01-29 Tyk2阻害薬の剤形

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022517368A Active JP7812785B2 (ja) 2019-09-18 2020-09-18 Tyk2阻害薬の剤形
JP2025124835A Pending JP2025163082A (ja) 2019-09-18 2025-07-25 Tyk2阻害薬の徐放性剤形
JP2026012729A Pending JP2026090315A (ja) 2019-09-18 2026-01-29 Tyk2阻害薬の剤形

Country Status (21)

Country Link
US (4) US12521390B2 (cg-RX-API-DMAC7.html)
EP (3) EP4031110B1 (cg-RX-API-DMAC7.html)
JP (4) JP7719770B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220066105A (cg-RX-API-DMAC7.html)
CN (8) CN119424434A (cg-RX-API-DMAC7.html)
AU (2) AU2020349524B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022004216A2 (cg-RX-API-DMAC7.html)
CA (2) CA3151369A1 (cg-RX-API-DMAC7.html)
DK (1) DK4031110T3 (cg-RX-API-DMAC7.html)
ES (2) ES3060149T3 (cg-RX-API-DMAC7.html)
FI (1) FI4031110T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260058T1 (cg-RX-API-DMAC7.html)
IL (3) IL291452B1 (cg-RX-API-DMAC7.html)
LT (1) LT4031110T (cg-RX-API-DMAC7.html)
MX (4) MX2022003146A (cg-RX-API-DMAC7.html)
PL (1) PL4031110T3 (cg-RX-API-DMAC7.html)
PT (1) PT4031110T (cg-RX-API-DMAC7.html)
RS (1) RS67803B1 (cg-RX-API-DMAC7.html)
SI (1) SI4031110T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600127T1 (cg-RX-API-DMAC7.html)
WO (2) WO2021055652A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291452B1 (en) * 2019-09-18 2026-06-01 Bristol Myers Squibb Co Dosage forms for TYK2 inhibitors
US20240325388A1 (en) * 2020-09-18 2024-10-03 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
KR20240065283A (ko) 2021-09-23 2024-05-14 브리스톨-마이어스 스큅 컴퍼니 Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
JP2024539703A (ja) * 2021-10-28 2024-10-29 ブリストル-マイヤーズ スクイブ カンパニー デュークラバシチニブの局所製剤
WO2023181075A1 (en) * 2022-03-24 2023-09-28 Dr. Reddy's Laboratories Limited Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof
AR128868A1 (es) * 2022-03-25 2024-06-19 Nimbus Lakshmi Inc Formulaciones de inhibidor de tyk2 y métodos para elaborarlas
WO2024176263A1 (en) * 2023-02-22 2024-08-29 Cipla Limited Deucravacitinib amorphous solid dispersions and polymorphs thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
ATE433318T1 (de) 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ES2310164T3 (es) 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
DK1242055T3 (da) 1999-12-23 2008-07-21 Pfizer Prod Inc Hydrogelstyret doseringsform til lægemidler
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
BR0307332A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
CN101152158B (zh) 2007-08-21 2010-05-26 浙江大学 一种药物的双层芯渗透泵片的制备方法
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
US9095585B2 (en) 2011-07-21 2015-08-04 Bristol-Myers Squibb Company Bioavailable compositions of amorphous piperidinyl compounds
TWI673051B (zh) * 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈(enzalutamide)之調和物
EP2895150A1 (en) 2012-09-11 2015-07-22 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
WO2014068402A2 (en) 2012-09-28 2014-05-08 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds
HRP20220766T1 (hr) * 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
JP6634368B2 (ja) 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
LT3601268T (lt) 2017-03-30 2021-05-25 Bristol-Myers Squibb Company 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazino-3-karboksamido gavimo būdas
CN118994118A (zh) 2018-05-31 2024-11-22 百时美施贵宝公司 化合物的结晶形式
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
IL291452B1 (en) * 2019-09-18 2026-06-01 Bristol Myers Squibb Co Dosage forms for TYK2 inhibitors
US20240325388A1 (en) * 2020-09-18 2024-10-03 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores

Similar Documents

Publication Publication Date Title
JP2022548687A5 (cg-RX-API-DMAC7.html)
US11090269B1 (en) Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
JP2019147832A5 (cg-RX-API-DMAC7.html)
JP2023123773A5 (cg-RX-API-DMAC7.html)
JP2023540137A5 (cg-RX-API-DMAC7.html)
JP2024539891A5 (cg-RX-API-DMAC7.html)
US20210113472A1 (en) Pharmaceutical composition comprising a potent inhibitor of urat1
JP2017525712A5 (cg-RX-API-DMAC7.html)
JP2017523206A5 (cg-RX-API-DMAC7.html)
EP2205279B1 (en) Pharmaceutical combination of aliskiren and valsartan
JP2007503414A5 (cg-RX-API-DMAC7.html)
HUP0201687A2 (en) Oral administration form for administering a fixed tramadol and diclofenac combination
JP2007503414A (ja) 新規なロピニロール処方
JP2019513800A (ja) メサラジンの経口薬学的組成物
JP2024001089A5 (cg-RX-API-DMAC7.html)
WO2015029074A2 (en) Compositions of eltrombopag
WO2005055955B1 (en) DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
JP2020511419A5 (cg-RX-API-DMAC7.html)
JP2024536609A5 (cg-RX-API-DMAC7.html)
JP5552434B2 (ja) 固形医薬製剤
JP2018538289A (ja) アプレミラスト徐放性製剤
US20150140089A1 (en) Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
CN115297848A (zh) 一种非布司他片
JP2008503540A5 (cg-RX-API-DMAC7.html)
RU2018137323A (ru) Пероральные фармацевтические композиции никотинамида